Suppressing activated myeloid cells with CTLA4-Ig (Abatacept/Orencia ®), which binds to CD80 and CD86 and prevents interaction with CD28, in combination with subcutaneous low dose IL-2 could improve Treg survival and function in ALS. Here, CTLA4 is linked to amyotrophic lateral sclerosis.